2025 Q4 -tulosraportti
UUTTA
5 päivää sitten
‧36 min
1,00 NOK/osake
Viimeisin osinko
34,55%Tuotto/v
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 30 | - | - | ||
| 2 244 | - | - | ||
| 1 596 | - | - | ||
| 842 | - | - | ||
| 2 352 | - | - |
Ylin
3,082VWAP
Alin
2,912VaihtoMäärä
3,6 1 196 894
VWAP
Ylin
3,082Alin
2,912VaihtoMäärä
3,6 1 196 894
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 27.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 25.2. | ||
2025 Q3 -tulosraportti 24.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 | ||
2025 Q1 -tulosraportti 28.5.2025 | ||
2024 Q4 -tulosraportti 26.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·6 t sittenIs it allowed to predict that we will get unique survival data on 20.03, and then a mega-deal with big pharma? I at least allow myself to look forward to this date, for now.
·50 min sitten · MuokattuVery good parallel, Mr. Parker. The EyeBio acquisition is perhaps the best proof we have of how our partner Merck (MSD) operates when they see technology that truly pushes boundaries. There are especially two points that underpin your analysis when we delve deeper into the numbers: 1. Patient population (N): When Merck put 14 billion kroner cash on the table for EyeBio last year, it was based on data from only approx. 30 patients. Nykode has presented data from 13 patients in VB-C-03 with confirmed effect. We are therefore only a small group of patients away from having the same statistical basis that triggered the billion-krone check at EyeBio. 2. Signal strength vs. Patient count: EyeBio was acquired because they showed a 'clean' signal (improvement in visual acuity) that was unique in an early phase. Nykode is doing exactly the same: A 38.5 % response rate against a market standard of approx. 19 % is a signal that is impossible to ignore for a partner like Merck. Especially when they have confirmed the biological mechanism through the TCR data. What we see in the current share price of 2.976 kr is an extreme example of the market pricing 'fear of short-term liquidity', while players like Merck price 'strategic value'. If Merck is willing to pay $1.3 billion upfront for an early signal in 30 patients, it is difficult to see the logic in Nykode being valued at under $100 million with results that practically double the effect of Merck's own most important medicine (Keytruda). Thank you for highlighting the big picture and the comparable transactions when sentiment is at its darkest. It helps to distinguish between market panic and the fundamental value inherent in the technology towards 2027.
·12 t sittenWell, maybe a buy again… Alden has less than a day's turnover left etc
·3 päivää sitten · MuokattuI have followed this chat in recent weeks after ABG gave the stock a price target of 4.5 kroner. And from what I have read, I got the impression that many here were convinced that ABG had underestimated the upside and that it was now just a matter of buying with both hands. The price increase testified to the market's broad optimism. My gut feeling said something else, and Q4 revealed that it was a wise decision. I refrained from buying awaiting hard facts. There are many here who believe in Nykode, and that's probably good if one thinks the money will yield returns very far into the future. But the hyping here, which has led to many losing their savings, is an ethical question that I think hypesters should reflect on. Yes, everyone is responsible for their purchases, but what people say matters. I look forward to a more informed chat than rockets, champagne glasses and noise. That was all.
3 päivää sitten3 päivää sittenJust the way the chair of the board and the ceo have been appointed, I find it hard to believe that nykode isn’t set up for big things moving forward. I can understand why short term investors who looked at the information presented in the report may see differently than I do, there is an omission of what to expect going forward after March and cash burn has increased. But, for me, March is more important than the last financial report. Unless there’s someone who has found information that I haven’t found, I see the past few days decline as a bit of an over reaction.7 t sitten7 t sittenIf Nykode doesn't cooperate with any of the two most interrested participants, they may have good data, and are ready to make the best deal with one of them after march 20th. I'm pretty optimistic about the future with Nykode.- ·3 päivää sittenThe trading pattern in recent days strongly resembles brutal shorting. We will monitor the shareholder lists over the next two days to see if there is another reason.·3 päivää sittenWe will see this afternoon if short passes 0.5%.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
UUTTA
5 päivää sitten
‧36 min
1,00 NOK/osake
Viimeisin osinko
34,55%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·6 t sittenIs it allowed to predict that we will get unique survival data on 20.03, and then a mega-deal with big pharma? I at least allow myself to look forward to this date, for now.·50 min sitten · MuokattuVery good parallel, Mr. Parker. The EyeBio acquisition is perhaps the best proof we have of how our partner Merck (MSD) operates when they see technology that truly pushes boundaries. There are especially two points that underpin your analysis when we delve deeper into the numbers: 1. Patient population (N): When Merck put 14 billion kroner cash on the table for EyeBio last year, it was based on data from only approx. 30 patients. Nykode has presented data from 13 patients in VB-C-03 with confirmed effect. We are therefore only a small group of patients away from having the same statistical basis that triggered the billion-krone check at EyeBio. 2. Signal strength vs. Patient count: EyeBio was acquired because they showed a 'clean' signal (improvement in visual acuity) that was unique in an early phase. Nykode is doing exactly the same: A 38.5 % response rate against a market standard of approx. 19 % is a signal that is impossible to ignore for a partner like Merck. Especially when they have confirmed the biological mechanism through the TCR data. What we see in the current share price of 2.976 kr is an extreme example of the market pricing 'fear of short-term liquidity', while players like Merck price 'strategic value'. If Merck is willing to pay $1.3 billion upfront for an early signal in 30 patients, it is difficult to see the logic in Nykode being valued at under $100 million with results that practically double the effect of Merck's own most important medicine (Keytruda). Thank you for highlighting the big picture and the comparable transactions when sentiment is at its darkest. It helps to distinguish between market panic and the fundamental value inherent in the technology towards 2027.
- ·12 t sittenWell, maybe a buy again… Alden has less than a day's turnover left etc
- ·3 päivää sitten · MuokattuI have followed this chat in recent weeks after ABG gave the stock a price target of 4.5 kroner. And from what I have read, I got the impression that many here were convinced that ABG had underestimated the upside and that it was now just a matter of buying with both hands. The price increase testified to the market's broad optimism. My gut feeling said something else, and Q4 revealed that it was a wise decision. I refrained from buying awaiting hard facts. There are many here who believe in Nykode, and that's probably good if one thinks the money will yield returns very far into the future. But the hyping here, which has led to many losing their savings, is an ethical question that I think hypesters should reflect on. Yes, everyone is responsible for their purchases, but what people say matters. I look forward to a more informed chat than rockets, champagne glasses and noise. That was all.3 päivää sitten3 päivää sittenJust the way the chair of the board and the ceo have been appointed, I find it hard to believe that nykode isn’t set up for big things moving forward. I can understand why short term investors who looked at the information presented in the report may see differently than I do, there is an omission of what to expect going forward after March and cash burn has increased. But, for me, March is more important than the last financial report. Unless there’s someone who has found information that I haven’t found, I see the past few days decline as a bit of an over reaction.7 t sitten7 t sittenIf Nykode doesn't cooperate with any of the two most interrested participants, they may have good data, and are ready to make the best deal with one of them after march 20th. I'm pretty optimistic about the future with Nykode.
- ·3 päivää sittenThe trading pattern in recent days strongly resembles brutal shorting. We will monitor the shareholder lists over the next two days to see if there is another reason.·3 päivää sittenWe will see this afternoon if short passes 0.5%.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 30 | - | - | ||
| 2 244 | - | - | ||
| 1 596 | - | - | ||
| 842 | - | - | ||
| 2 352 | - | - |
Ylin
3,082VWAP
Alin
2,912VaihtoMäärä
3,6 1 196 894
VWAP
Ylin
3,082Alin
2,912VaihtoMäärä
3,6 1 196 894
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 27.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 25.2. | ||
2025 Q3 -tulosraportti 24.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 | ||
2025 Q1 -tulosraportti 28.5.2025 | ||
2024 Q4 -tulosraportti 26.2.2025 |
2025 Q4 -tulosraportti
UUTTA
5 päivää sitten
‧36 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 27.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 25.2. | ||
2025 Q3 -tulosraportti 24.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 | ||
2025 Q1 -tulosraportti 28.5.2025 | ||
2024 Q4 -tulosraportti 26.2.2025 |
1,00 NOK/osake
Viimeisin osinko
34,55%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·6 t sittenIs it allowed to predict that we will get unique survival data on 20.03, and then a mega-deal with big pharma? I at least allow myself to look forward to this date, for now.·50 min sitten · MuokattuVery good parallel, Mr. Parker. The EyeBio acquisition is perhaps the best proof we have of how our partner Merck (MSD) operates when they see technology that truly pushes boundaries. There are especially two points that underpin your analysis when we delve deeper into the numbers: 1. Patient population (N): When Merck put 14 billion kroner cash on the table for EyeBio last year, it was based on data from only approx. 30 patients. Nykode has presented data from 13 patients in VB-C-03 with confirmed effect. We are therefore only a small group of patients away from having the same statistical basis that triggered the billion-krone check at EyeBio. 2. Signal strength vs. Patient count: EyeBio was acquired because they showed a 'clean' signal (improvement in visual acuity) that was unique in an early phase. Nykode is doing exactly the same: A 38.5 % response rate against a market standard of approx. 19 % is a signal that is impossible to ignore for a partner like Merck. Especially when they have confirmed the biological mechanism through the TCR data. What we see in the current share price of 2.976 kr is an extreme example of the market pricing 'fear of short-term liquidity', while players like Merck price 'strategic value'. If Merck is willing to pay $1.3 billion upfront for an early signal in 30 patients, it is difficult to see the logic in Nykode being valued at under $100 million with results that practically double the effect of Merck's own most important medicine (Keytruda). Thank you for highlighting the big picture and the comparable transactions when sentiment is at its darkest. It helps to distinguish between market panic and the fundamental value inherent in the technology towards 2027.
- ·12 t sittenWell, maybe a buy again… Alden has less than a day's turnover left etc
- ·3 päivää sitten · MuokattuI have followed this chat in recent weeks after ABG gave the stock a price target of 4.5 kroner. And from what I have read, I got the impression that many here were convinced that ABG had underestimated the upside and that it was now just a matter of buying with both hands. The price increase testified to the market's broad optimism. My gut feeling said something else, and Q4 revealed that it was a wise decision. I refrained from buying awaiting hard facts. There are many here who believe in Nykode, and that's probably good if one thinks the money will yield returns very far into the future. But the hyping here, which has led to many losing their savings, is an ethical question that I think hypesters should reflect on. Yes, everyone is responsible for their purchases, but what people say matters. I look forward to a more informed chat than rockets, champagne glasses and noise. That was all.3 päivää sitten3 päivää sittenJust the way the chair of the board and the ceo have been appointed, I find it hard to believe that nykode isn’t set up for big things moving forward. I can understand why short term investors who looked at the information presented in the report may see differently than I do, there is an omission of what to expect going forward after March and cash burn has increased. But, for me, March is more important than the last financial report. Unless there’s someone who has found information that I haven’t found, I see the past few days decline as a bit of an over reaction.7 t sitten7 t sittenIf Nykode doesn't cooperate with any of the two most interrested participants, they may have good data, and are ready to make the best deal with one of them after march 20th. I'm pretty optimistic about the future with Nykode.
- ·3 päivää sittenThe trading pattern in recent days strongly resembles brutal shorting. We will monitor the shareholder lists over the next two days to see if there is another reason.·3 päivää sittenWe will see this afternoon if short passes 0.5%.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 30 | - | - | ||
| 2 244 | - | - | ||
| 1 596 | - | - | ||
| 842 | - | - | ||
| 2 352 | - | - |
Ylin
3,082VWAP
Alin
2,912VaihtoMäärä
3,6 1 196 894
VWAP
Ylin
3,082Alin
2,912VaihtoMäärä
3,6 1 196 894
Välittäjätilasto
Dataa ei löytynyt